巴西内脏利什曼病住院患者用氨苯砜不良反应：病例系列研究。
Adverse reactions to meglumine antimoniate in Brazilian inpatients with visceral leishmaniases: A case series.
机构信息
Santa Casa de Misericórdia de Belo Horizonte, Belo Horizonte, Brazil.
Faculdade de Farmácia, Universidade Federal de Minas Gerais, Belo Horizonte, Brazil.
出版信息
J Clin Pharm Ther. 2020 Jun;45(3):573-576. doi: 10.1111/jcpt.13089. Epub 2019 Dec 2.
WHAT IS KNOWN AND OBJECTIVES
Adverse drug reactions (ADR) related to the treatment of visceral leishmaniasis (VL) can cause severe clinical complications. We report a case series of ADR in hospitalized VL patients on meglumine antimoniate (MA).
CASE DESCRIPTION
Seven cases of patients taking MA had at least one objective evidence for suspected ADR, including electrocardiographic, laboratory or clinical alteration.
WHAT IS NEW AND CONCLUSION
Meglumine antimoniate is highly toxic. Adherence to treatment guidelines is important. Pharmacists working in multidisciplinary teams may contribute to early detection and management of MA therapy-related ADR.
已知和目的
与内脏利什曼病（VL）治疗相关的药物不良反应（ADR）可导致严重的临床并发症。我们报告了一组住院接受葡甲胺锑治疗（MA）的 VL 患者的 ADR 病例系列。
病例描述
7 例接受 MA 治疗的患者至少有一项疑似 ADR 的客观证据，包括心电图、实验室或临床改变。
新内容和结论
葡甲胺锑毒性很高。遵守治疗指南很重要。在多学科团队中工作的药剂师可能有助于早期发现和管理 MA 治疗相关的 ADR。
Zotero 插件